Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02418104 · ClinicalTrials.gov registry record · Phase 1
Assessing the Immunogenicity of 2 Subcutaneous Doses of CHS-1701 (Coherus Pegfilgrastim) With 2 Subcutaneous Doses Neulasta®
A Phase 1 study, sponsored by Coherus Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 303
- Enrollment target
NCT02418104 is a Phase 1 study that has completed, run by Coherus Oncology. The registered enrollment target is 303 participants.
The verdict
NCT02418104, a Phase 1 study, has completed, sponsored by Coherus Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 303 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, 2-period parallel study in healthy subjects to assess immunogenicity and safety of two sequential 6 mg subcutaneous (SC) injections of CHS-1701 compared with two sequential 6 mg SC injections of Neulasta®.
Interventions
- DRUG CHS-1701
- DRUG Pegfilgrastim (Neulasta)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 303 participants |
| Start Date | 2015-05 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02418104
The ClinicalTrials.gov registry entry for NCT02418104 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 303 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Coherus Oncology, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CHS-1701 is the first listed.
NCT02418104 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02418104 about?
NCT02418104 is a clinical study titled "Assessing the Immunogenicity of 2 Subcutaneous Doses of CHS-1701 (Coherus Pegfilgrastim) With 2 Subcutaneous Doses Neulasta®". This is a randomized, double-blind, 2-period parallel study in healthy subjects to assess immunogenicity and safety of two sequential 6 mg subcutaneous (SC) injections of CHS-1701 compared with two sequential 6 mg SC injections of Neulasta®.
What is the current status of trial NCT02418104?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 303 participants. The study started on 2015-05. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02418104?
The interventions under investigation include: CHS-1701 (DRUG), Pegfilgrastim (Neulasta) (DRUG).
Who is sponsoring clinical trial NCT02418104?
This trial is sponsored by Coherus Oncology, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.